Abstract
We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients. In total 24 adverse events in 21 patients were reported. Treatment with TNF-alpha inhibitors seems to be safe and effective for children and adolescents with rheumatologic diseases.
MeSH terms
-
Adolescent
-
Adverse Drug Reaction Reporting Systems
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Juvenile / drug therapy
-
Child
-
Drug Interactions
-
Drug Therapy, Combination
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use*
-
Infliximab
-
Product Surveillance, Postmarketing
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Registries*
-
Rheumatic Diseases / drug therapy*
-
Switzerland
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Uveitis / drug therapy
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Etanercept